ConductScience.org, home

Trial · NCT02810483

Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks

NCT02810483, Phase 3, Terminated, Assistance Publique - Hôpitaux de Paris

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks. Trials, record NCT02810483. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02810483

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks
NCT number
NCT02810483
Status
Terminated
Phases
Phase 3
Enrollment
69 participants, actual
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Conditions
Prader-Willi Syndrome
Interventions
Topiramate, Placebo Comparator
First posted
2016-06-23
Last updated
2018-04-11

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryClinical Global Impression Improvementat 8 weeks (endpoint)Endpoint CGI score at 1 or 2 will make consider the patient as a responder. A 7 items scale will be used
SecondaryWeight and sizeat 8 weeks (endpoint)Weight and size (BMI in kg/m2)
SecondarySelf-Injury Behavior Scale ECAHA,at 8 weeks (endpoint)Comparison between baseline score and endpoint score
SecondarySelf-Injury Behavior, CONNERS Impulsivityat 8 weeks (endpoint)CONNERS Impulsivity comparison between baseline score and endpoint score
SecondarySelf-Injury Behavior,Dickensat 8 weeks (endpoint)Dickens comparison between baseline score and endpoint score
SecondaryC-SHARP (Chid and Adolescent), appearance of positive suicide item responseat 8 weeks (endpoint)
SecondaryA-SHARP (Adult), appearance of positive suicide item responseat 8 weeks (endpoint)A-SHARP (Adult), appearance of positive suicide item response
SecondarySafety Assessmentat 8 weeks (endpoint)The proportion of patients stopped the treatment, of patients with adverse events and prematurely discontinued treatment due to an adverse event will be estimated.
SecondaryBiological assessmentat 8 weeks (endpoint)The number of patients with abnormal values and / or modified from the baseline values will be evaluated

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02810483

GET https://conductscience.org/api/trials/v1/NCT02810483/registered